Your browser doesn't support javascript.
loading
Cytochrome P-450-mediated herb and food-drug interactions can be identified in cancer patients through patient self-reporting with a tablet application: results of a prospective observational study.
Gougis, P; Géraud, A; Hilmi, M; Vozy, A; Campedel, L; Abbar, B; Allio, C; De Chatillon, S; Portalier, A; Lapray, F; Choquet, S; Spano, J-P; Reyal, F; Mir, O; Funck-Brentano, C; Hamy, A-S.
Afiliação
  • Gougis P; Residual Tumor & Response to Treatment Laboratory, RT2Lab, INSERM, U932 Immunity and Cancer, Institut Curie, Université Paris, Paris, France; Sorbonne Université, Institut national de la santé et de la recherche médicale (INSERM), Assistance Publique-Hôpitaux de Paris (AP-HP), Clinical Investiga
  • Géraud A; Department of Drug Development, Gustave Roussy Cancer Center, Villejuif, France.
  • Hilmi M; Medical Oncology Department, Curie Institute, Versailles Saint-Quentin University (UVQ), Paris Saclay University, Saint-Cloud, France.
  • Vozy A; Department of Medical Oncology, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Paris, France.
  • Campedel L; Department of Medical Oncology, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Paris, France.
  • Abbar B; Department of Medical Oncology, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Paris, France.
  • Allio C; Sorbonne Université, Institut national de la santé et de la recherche médicale (INSERM), Assistance Publique-Hôpitaux de Paris (AP-HP), Clinical Investigation Center (CIC-1901), Department of Pharmacology, Pitié-Salpêtrière Hospital, Paris, France; Department of Medical Oncology, Assistance Publique
  • De Chatillon S; Sorbonne Université, Institut national de la santé et de la recherche médicale (INSERM), Assistance Publique-Hôpitaux de Paris (AP-HP), Clinical Investigation Center (CIC-1901), Department of Pharmacology, Pitié-Salpêtrière Hospital, Paris, France; Department of Medical Oncology, Assistance Publique
  • Portalier A; Clinical Hematology Unit, Groupe Hospitalier Pitié-Salpêtrière, AP-HP Sorbonne Université, Paris, France.
  • Lapray F; Department of Medical Oncology, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Paris, France.
  • Choquet S; Clinical Hematology Unit, Groupe Hospitalier Pitié-Salpêtrière, AP-HP Sorbonne Université, Paris, France.
  • Spano JP; Department of Medical Oncology, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Paris, France.
  • Reyal F; Residual Tumor & Response to Treatment Laboratory, RT2Lab, INSERM, U932 Immunity and Cancer, Institut Curie, Université Paris, Paris, France; Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Université Paris, Paris, France; Department of Surgical Oncology, Institut
  • Mir O; Department of Ambulatory Care, Gustave Roussy Cancer Campus, Villejuif, France.
  • Funck-Brentano C; Sorbonne Université, Institut national de la santé et de la recherche médicale (INSERM), Assistance Publique-Hôpitaux de Paris (AP-HP), Clinical Investigation Center (CIC-1901), Department of Pharmacology, Pitié-Salpêtrière Hospital, Paris, France.
  • Hamy AS; Residual Tumor & Response to Treatment Laboratory, RT2Lab, INSERM, U932 Immunity and Cancer, Institut Curie, Université Paris, Paris, France; Department of Medical Oncology, Institut Curie, Université Paris, Paris, France.
ESMO Open ; 7(6): 100650, 2022 12.
Article em En | MEDLINE | ID: mdl-36493603

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article